In this manuscript, we review the current progress of utilizing ultrasound-guided diffuse optical tomography (US-guided DOT) for predicting and monitoring neoadjuvant chemotherapy (NAC) outcomes of breast cancer patients. We also report the recent advance on optical tomography systems toward portable and robust clinical use at multiple clinical sites. The first patient who has been closely monitored before NAC, at day 2, day 8, end of first three cycles of NAC, and before surgery is given as an example to demonstrate the potential of US-guided DOT technique.
FisherBBrownAMamounasEWieandSRobidouxAMargoleseRG. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15:2483-93.
2.
WolmarkNWangJMamounasEBryantJFisherB.Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96-102.
3.
GampenriederSPRinnerthalerGGreilR.Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future. J Oncol. 2013;2013:732047.
4.
RastogiPAndersonSJBearHDGeyerCEKahlenbergMSRobidouxA. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778-85.
5.
BardiaABaselgaJ.Neoadjuvant therapy as a platform for drug development and approval in breast cancer. Clin Cancer Res. 2013;19(23):6360-70.
6.
SorlieTPerouCMTibshiraniRAasTGeislerSJohnsenH. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-74.
7.
SotiriouCNeoSYMcShaneLMKornELLongPMJazaeriA. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003;100:10393-8.
8.
RouzierRPerouCMSymmansWFIbrahimNCristofanilliMAndersonK. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678-85.
9.
VenkitaramanR.Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. Expert Rev Anticancer Ther. 2010;10(2):199-207.
10.
ChangHR.Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer. 2010;116(12):2856-67.
11.
von MinckwitzGMartinM. Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol. 2012;23(Suppl. 6):vi35-9.
12.
LipsEHMulderLde RondeJJMandjesIAVincentAVrancken PeetersMT. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat. 2012;131(3):827-36.
13.
SwainSMSoraceRABagleyCSDanforthDNJrBaderJWesleyMN. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res. 1987;47:3889-94.
14.
BooserDJHortobagyiGN.Treatment of locally advanced breast cancer. Semin Oncol. 1992;19:278-85.
15.
CocconiGDi BlasioBAlbertiGBisagniGBottiEPeracchiaG.Problems in evaluating response of primary breast cancer to systemic therapy. Breast Cancer Res Treat. 1984;4:309-13.
16.
SegelMCPaulusDDHortobagyiGN.Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. Radiology. 1988;169:49-54.
17.
WarrenRMBobrowLGEarlHMBrittonPDGopalanDPurushothamAD. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy?Br J Cancer. 2004;90:1349-60.
18.
LooCEStraverMERodenhuisSMullerSHWesselingJVrancken PeetersMJ. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol. 2011;29(6):660-6.
HumbertOCochetARiedingerJMBerriolo-RiedingerAArnouldLCoudertB. HER2-positive breast cancer: 18F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41(8):1525-33. doi:10.1007/s00259-014-2739-1.
21.
MghangaFPLanXBakariKHLiCZhangY.Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis. Clin Breast Cancer. 2013;13:271-9.
22.
HumbertOBerriolo-RiedingerACochetAGauthierMCharon-BarraCGuiuS. Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer. Nucl Med Mol Imaging. 2014;41(3):416-27. doi:10.1007/s00259-013-2616-3.
23.
CerussiAHsiangDShahNMehtaRDurkinAButlerJ. Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy. Proc Natl Acad Sci U S A. 2007;104(10):4014-9.
24.
ChoeRDurduranT.Diffuse optical monitoring of the neoadjuvant breast cancer therapy. IEEE J Sel Top Quantum Electron. 2012;18(4):1367-86.
25.
ZhuQTannenbaumSHegdePKaneMXuCKurtzmanSH.Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization. Neoplasia. 2008;10:1028-40.
26.
JiangSPogueBWCarpenterCMPoplackSPWellsWAKogelCA. Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes. Radiology. 2009;252:551-60.
27.
SolimanHGunasekaraARycroftMZubovitsJDentRSpayneJ. Functional imaging using diffuse optical spectroscopy of neoadjuvant chemotherapy response in women with locally advanced breast cancer. Clin Cancer Res. 2010;16(9):2605-14.
28.
RoblyerDUedaSCerussiATanamaiWDurkinAMehtaR. Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment. Proc Natl Acad Sci U S A. 2011;108:14626-31.
29.
ZhuQKurtzmanSHegdePTannenbaumSKaneMHuangMM. Utilizing optical tomography with ultrasound localization to image heterogeneous hemoglobin distribution in large breast cancers. Neoplasia. 2005;7(3):263-70.
30.
ZhuQDeFuscoPARicciAJrCroninEBHegdePUKaneM. Assessing response to neoadjuvant chemotherapy by using US-guided near-infrared tomography. Radiology. 2013;266(2):433-42.
31.
UedaSRoblyerDCerussiADurkinALeprouxASantoroY. Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy. Cancer Res. 2012;72(17):4318-28. doi:10.1158/0008-5472.CAN-12-0056.
32.
FalouOSolimanHSadeghi-NainiAIradjiSLemon-WongSZubovitsJ. Diffuse optical spectroscopy evaluation of treatment response in women with locally advanced breast cancer receiving neoadjuvant chemotherapy. Transl Oncol. 2012;5(4):238-46.
33.
BuschDChoeRRosenMAGuoWDurduranTFeldmanMD. Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy. Biomed Opt Express. 2013;4(1):105-21.
34.
JiangSPogueBWKaufmanPAGuiJJermynMFrazeeTE. Predicting breast tumor response to neoadjuvant chemotherapy with Diffuse Optical Spectroscopic Tomography prior to treatment. 2014;20(23);6006-15.
35.
ZhuQWangLTannenbaumSRicciADeFuscoPHegdeP.Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near infrared imaging parameters and tumor pathologic criteria. Breast Cancer Res. 2014;16(5):456.
36.
ChenNGGuoPYanSPiaoDZhuQ.Simultaneous near infrared diffusive light and ultrasound imaging. Applied Optics. 2001;40(34):6367-280.
37.
ZhuQCroninEBCurrierAAVineHSHuangMChenN. Benign versus malignant breast masses: optical differentiation with US-guided optical imaging reconstruction. Radiology. 2005;237(1):57-66.
38.
ZhuQHuangMChenNZarfosKJagjivanBKaneM. Ultrasound-guided optical tomographic imaging of malignant and benign breast lesions: initial clinical results of 19 cases. Neoplasia. 2003;5(5):379-88.
39.
ZhuQHegdePURicciAJrKaneMCroninEBArdeshirpourY. Early-stage invasive breast cancers: potential role of optical tomography with US localization in assisting diagnosis. Radiology. 2010;256(2):367-78. doi:10.1148/radiol.10091237.
40.
ZhuQChenNKurtzmanSH.Imaging tumor angiogenesis by use of combined near-infrared diffusive light and ultrasound. Opt Lett. 2003;28(5):337-9.
41.
KleinbaumDKupperLMullerKNizamA.Applied Regression Analysis and Other Multivariable Methods, 3rd ed.Duxbury Press; 1998.
42.
OgstonKNMillerIDPayneSHutcheonAWSarkarTKSmithI. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12:320-7.
